The Board of Directors at its meeting held today have approved Audited Financial Results of the Company for half and financial year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 5.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hemant Surgical Industries Ltd has released its audited financial results for FY2026 (standalone and consolidated) ending March 31, 2026. Total revenue grew significantly to ₹23,098.71 lakhs from ₹10,652.66 lakhs in the prior year, representing growth of approximately 117%. Profit after tax more than doubled to ₹1,823.34 lakhs from ₹813.21 lakhs, a growth of 124%. Basic EPS stands at ₹15.42 per share. The company raised ₹6,152.71 lakhs through equity shares and warrants during the year, with ₹4,663.63 lakhs already utilized for capital expenditure, debt repayment and working capital. Statutory auditors ADV & Associates have issued an unmodified (clean) audit opinion on both standalone and consolidated results.
Strong financial performance with revenue and profit both more than doubling year-on-year. The clean audit opinion with no qualifications signals financial health and should be viewed positively by investors.